JP7591348B2 - インターフェロン遺伝子刺激因子依存性シグナル伝達のアゴニストとしての環状ジヌクレオチド - Google Patents
インターフェロン遺伝子刺激因子依存性シグナル伝達のアゴニストとしての環状ジヌクレオチド Download PDFInfo
- Publication number
- JP7591348B2 JP7591348B2 JP2019544894A JP2019544894A JP7591348B2 JP 7591348 B2 JP7591348 B2 JP 7591348B2 JP 2019544894 A JP2019544894 A JP 2019544894A JP 2019544894 A JP2019544894 A JP 2019544894A JP 7591348 B2 JP7591348 B2 JP 7591348B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- cancer
- disease
- pharmaceutical composition
- drug delivery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022187897A JP2023022165A (ja) | 2017-02-21 | 2022-11-25 | インターフェロン遺伝子刺激因子依存性シグナル伝達のアゴニストとしての環状ジヌクレオチド |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762461642P | 2017-02-21 | 2017-02-21 | |
| US62/461,642 | 2017-02-21 | ||
| PCT/US2018/019015 WO2018156625A1 (en) | 2017-02-21 | 2018-02-21 | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022187897A Division JP2023022165A (ja) | 2017-02-21 | 2022-11-25 | インターフェロン遺伝子刺激因子依存性シグナル伝達のアゴニストとしての環状ジヌクレオチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020508310A JP2020508310A (ja) | 2020-03-19 |
| JP2020508310A5 JP2020508310A5 (enExample) | 2021-04-08 |
| JP7591348B2 true JP7591348B2 (ja) | 2024-11-28 |
Family
ID=63253365
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019544894A Active JP7591348B2 (ja) | 2017-02-21 | 2018-02-21 | インターフェロン遺伝子刺激因子依存性シグナル伝達のアゴニストとしての環状ジヌクレオチド |
| JP2022187897A Withdrawn JP2023022165A (ja) | 2017-02-21 | 2022-11-25 | インターフェロン遺伝子刺激因子依存性シグナル伝達のアゴニストとしての環状ジヌクレオチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022187897A Withdrawn JP2023022165A (ja) | 2017-02-21 | 2022-11-25 | インターフェロン遺伝子刺激因子依存性シグナル伝達のアゴニストとしての環状ジヌクレオチド |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US10933078B2 (enExample) |
| EP (1) | EP3585379A4 (enExample) |
| JP (2) | JP7591348B2 (enExample) |
| CA (1) | CA3053568A1 (enExample) |
| WO (1) | WO2018156625A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL280430B2 (en) | 2016-03-18 | 2023-11-01 | Univ Texas | Cyclic dinucleotide compounds and methods of use |
| CA3029644A1 (en) | 2016-07-06 | 2018-01-11 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
| WO2018100558A2 (en) | 2016-12-01 | 2018-06-07 | Takeda Pharmaceutical Company Limited | Cyclic dinucleotide |
| CA3053568A1 (en) * | 2017-02-21 | 2018-08-30 | Board Of Regents, The University Of Texas System | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling |
| EP3675859A4 (en) | 2017-08-31 | 2021-06-30 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR TREATMENT OF DISEASES |
| US11707531B2 (en) | 2017-09-11 | 2023-07-25 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
| WO2019051488A1 (en) | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE |
| WO2019084060A1 (en) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
| PH12020550585A1 (en) | 2017-11-10 | 2021-04-19 | Takeda Pharmaceuticals Co | Sting modulator compounds, and methods of making and using |
| WO2019125974A1 (en) | 2017-12-20 | 2019-06-27 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
| WO2020014127A1 (en) | 2018-07-10 | 2020-01-16 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
| SG11202101980VA (en) | 2018-09-12 | 2021-03-30 | Silverback Therapeutics Inc | Methods and composition for the treatment of disease with immune stimulatory conjugates |
| EP3873484B1 (en) | 2018-10-29 | 2023-08-23 | Venenum Biodesign, LLC | Novel sting agonists |
| US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
| CN114127082A (zh) * | 2019-05-09 | 2022-03-01 | 阿里戈斯治疗公司 | 作为sting调节剂的经修饰的环状二核苷化合物 |
| WO2021067644A1 (en) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
| US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| US20230141284A1 (en) | 2020-04-10 | 2023-05-11 | Ono Pharmaceutical Co., Ltd. | Cancer therapeutic method |
| KR20230047361A (ko) | 2020-07-01 | 2023-04-07 | 아르스 파마슈티컬스 인크. | 항-asgr1 항체 접합체 및 이의 용도 |
| JP7875196B2 (ja) * | 2020-10-20 | 2026-06-17 | タイリガンド バイオサイエンス（シャンハイ）リミテッド | 多機能環状ジヌクレオチド及びその使用 |
| JP7397996B2 (ja) | 2020-11-09 | 2023-12-13 | 武田薬品工業株式会社 | 抗体薬物コンジュゲート |
| WO2023020993A1 (en) * | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017027646A1 (en) | 2015-08-13 | 2017-02-16 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
| JP2018516903A (ja) | 2015-12-03 | 2018-06-28 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｓｔｉｎｇの調節因子としての環状プリンジヌクレオチド |
| JP2018534295A (ja) | 2015-10-28 | 2018-11-22 | アドゥロ バイオテック，インク． | 「インターフェロン遺伝子刺激因子」依存性シグナル伝達を活性化するための組成物および方法 |
| JP2019509339A (ja) | 2016-03-18 | 2019-04-04 | イミューン センサー リミテッド ライアビリティ カンパニー | 環状ジヌクレオチド化合物および使用方法 |
| JP2020503303A (ja) | 2016-12-20 | 2020-01-30 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | がんの処置のための環状ジヌクレオチドｓｔｉｎｇアゴニスト |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2858722B8 (en) | 2012-06-08 | 2018-02-21 | Aduro BioTech, Inc. | Compostions and methods for cancer immunotherapy |
| SG11201502796RA (en) | 2012-12-13 | 2015-05-28 | Aduro Biotech Inc | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| JP2016524593A (ja) * | 2013-04-29 | 2016-08-18 | メモリアル スローン−ケタリング キャンサー センター | セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法 |
| CU24377B1 (es) | 2013-05-18 | 2018-12-05 | Aduro Biotech Inc | Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting |
| EP2996472B1 (en) | 2013-05-18 | 2019-03-27 | Aduro Biotech, Inc. | Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling |
| EP3152217B1 (en) | 2014-06-04 | 2018-08-01 | GlaxoSmithKline Intellectual Property Development Limited | Cyclic di-nucleotides as modulators of sting |
| DK3233882T3 (da) | 2014-12-16 | 2020-01-27 | Kayla Therapeutics | Fluorinerede cykliske dinukleotider til cytokininduktion |
| EP3233191A1 (en) | 2014-12-16 | 2017-10-25 | Invivogen | Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment |
| GB201501462D0 (en) * | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| TWI706958B (zh) | 2015-03-10 | 2020-10-11 | 美商艾杜諾生物科技公司 | 活化「干擾素基因刺激因子」依賴性訊息傳導之組合物及方法 |
| US20180369268A1 (en) | 2015-12-16 | 2018-12-27 | Aduro Biotech, Inc. | Methods for identifying inhibitors of "stimulator of interferon gene"- dependent interferon production |
| WO2018100558A2 (en) | 2016-12-01 | 2018-06-07 | Takeda Pharmaceutical Company Limited | Cyclic dinucleotide |
| WO2018119117A1 (en) | 2016-12-22 | 2018-06-28 | The Regents Of The University Of California | Methods of producing cyclic dinucleotides |
| CA3053568A1 (en) | 2017-02-21 | 2018-08-30 | Board Of Regents, The University Of Texas System | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling |
| WO2018198084A1 (en) | 2017-04-27 | 2018-11-01 | Lupin Limited | Cyclic di-nucleotide compounds with tricyclic nucleobases |
| US11466047B2 (en) | 2017-05-12 | 2022-10-11 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| TWI808092B (zh) | 2017-08-30 | 2023-07-11 | 中國大陸商北京軒義醫藥科技有限公司 | 作為干擾素基因調節劑之刺激劑的環狀二核苷酸 |
| EP3675859A4 (en) | 2017-08-31 | 2021-06-30 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR TREATMENT OF DISEASES |
-
2018
- 2018-02-21 CA CA3053568A patent/CA3053568A1/en active Pending
- 2018-02-21 EP EP18757865.3A patent/EP3585379A4/en active Pending
- 2018-02-21 US US16/484,179 patent/US10933078B2/en active Active
- 2018-02-21 WO PCT/US2018/019015 patent/WO2018156625A1/en not_active Ceased
- 2018-02-21 JP JP2019544894A patent/JP7591348B2/ja active Active
-
2020
- 2020-10-07 US US17/065,304 patent/US11400108B2/en active Active
-
2022
- 2022-06-27 US US17/809,190 patent/US12036231B2/en active Active
- 2022-11-25 JP JP2022187897A patent/JP2023022165A/ja not_active Withdrawn
-
2024
- 2024-06-05 US US18/734,176 patent/US20250041324A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017027646A1 (en) | 2015-08-13 | 2017-02-16 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
| JP2018534295A (ja) | 2015-10-28 | 2018-11-22 | アドゥロ バイオテック，インク． | 「インターフェロン遺伝子刺激因子」依存性シグナル伝達を活性化するための組成物および方法 |
| JP2018516903A (ja) | 2015-12-03 | 2018-06-28 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｓｔｉｎｇの調節因子としての環状プリンジヌクレオチド |
| JP2019509339A (ja) | 2016-03-18 | 2019-04-04 | イミューン センサー リミテッド ライアビリティ カンパニー | 環状ジヌクレオチド化合物および使用方法 |
| JP2020503303A (ja) | 2016-12-20 | 2020-01-30 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | がんの処置のための環状ジヌクレオチドｓｔｉｎｇアゴニスト |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3053568A1 (en) | 2018-08-30 |
| EP3585379A1 (en) | 2020-01-01 |
| US10933078B2 (en) | 2021-03-02 |
| US20250041324A1 (en) | 2025-02-06 |
| US20190358254A1 (en) | 2019-11-28 |
| US11400108B2 (en) | 2022-08-02 |
| WO2018156625A1 (en) | 2018-08-30 |
| US20220347201A1 (en) | 2022-11-03 |
| US20210236531A1 (en) | 2021-08-05 |
| JP2023022165A (ja) | 2023-02-14 |
| EP3585379A4 (en) | 2020-12-02 |
| US12036231B2 (en) | 2024-07-16 |
| JP2020508310A (ja) | 2020-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12036231B2 (en) | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling | |
| JP7229907B2 (ja) | ＳＴＩＮＧ （ｓｔｉｍｕｌａｔｏｒ ｏｆ ｉｎｔｅｒｆｅｒｏｎ ｇｅｎｅｓ）アゴニストとしての環状ジヌクレオチド | |
| CN109843903B (zh) | 环二核苷酸化合物 | |
| JP6742534B2 (ja) | 修飾環状ジヌクレオチド化合物 | |
| US11858957B2 (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| JP6867395B2 (ja) | Ｓｔｉｎｇ活性と関連のある症状、例えば癌を治療するための環状ジヌクレオチド | |
| JP6411676B2 (ja) | Ｓｔｉｎｇの調節因子としての環状プリンジヌクレオチド | |
| US10894052B2 (en) | Heterocyclic inhibitors of ATR kinase | |
| KR20220150356A (ko) | 치료제 및 이의 접합체 | |
| JP2021519279A (ja) | 修飾環式ジヌクレオチド化合物 | |
| US20220194940A1 (en) | Heterocyclic inhibitors of tyrosine kinase | |
| EA046381B1 (ru) | Ингибиторы эктонуклеотидазы и способы их применения | |
| HK40049700B (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| HK40028148A (en) | Heterocyclic inhibitors of atr kinase | |
| HK40028148B (en) | Heterocyclic inhibitors of atr kinase | |
| HK40005913B (en) | Cyclic dinucleotide compounds | |
| HK40005913A (en) | Cyclic dinucleotide compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210222 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210222 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211124 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220222 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220406 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220726 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221125 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20221125 |
|
| C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20221206 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230116 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20230117 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20230317 |
|
| C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20230322 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240808 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20241118 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7591348 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |